PF-00299804: Clinical Trials

7 completed, 2 terminated. 9 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	9	Completed 7, Terminated 2
Phase 2	1	Completed 1

Follow PF-00299804: new trials by email Literature Review of PF-00299804 trials Research Report on PF-00299804

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8	Phase 1	Terminated	OHSU Knight Cancer Institute	2	2020-04-01	2024-03-04
Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck dacomitinib, Radiotherapy, Cisplatin - Squamous Cell Carcinoma of the Head and Neck	Phase 1	Completed	University Health Network, Toronto	12	2013-01-01	2016-06-13
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer PF-02341066, PF-00299804 - Non Small Cell Lung Cancer	Phase 1	Completed	Pfizer	70	2010-08-01	2015-10-28
Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment PF-00299804 - Oral Cavity Cancer	Phase 1 / Phase 2	Completed	University Health Network, Toronto	13	2010-05-01	2015-07-10
A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804 PF-00299804 - Non-Small Cell Lung Cancer (NSCLC)	Phase 1	Terminated	Pfizer	22	2010-02-01	2012-06-22
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks PF-00299804 - Carcinoma, Non-Small Cell, Neoplasm Metastasis	Phase 1	Completed	Pfizer	74	2008-12-15	2024-04-22
A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors PF-00299804 - Neoplasms	Phase 1	Completed	Pfizer	13	2008-11-01	2011-06-27
A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients PF-00299804 - Advanced Malignant Solid Tumors	Phase 1	Completed	Pfizer	16	2008-09-01	2017-08-02
Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors PF-00299804 - Neoplasms	Phase 1	Completed	Pfizer	121	2005-10-11	2018-12-21

Conditions studied

Carcinoma, Non-Small-Cell Lung (2)  ·  Neoplasm Metastasis (2)  ·  Neoplasms (2)  ·  Anemia (1)  ·  Blast Crisis (1)  ·  Breast Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Squamous Cell (1)  ·  Hematologic Neoplasms (1)  ·  Hodgkin Disease (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Leukemia, Myeloid, Accelerated Phase (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1)

Sponsors

Pfizer (6)  ·  University Health Network, Toronto (2)  ·  OHSU Knight Cancer Institute (1)

Countries

United States (6)  ·  Canada (2)  ·  Australia (1)  ·  France (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Spain (1)

Top investigators

Lara Davis, MD (1)  ·  Lillian Siu, M.D. (1)  ·  Lillian Siu, MD, FRCPC (1)

Results publications

PMID 21220471, PMID 22249430, PMID 25937431, PMID 39863139

NIH funding

2005 (1)